Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - ranitidine hydrochloride - oral tablet - 150mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

the boots company plc - ranitidine hydrochloride - oral tablet - 150mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - ranitidine hydrochloride - oral tablet - 150mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

ivax pharmaceuticals uk ltd - ranitidine hydrochloride - oral tablet - 150mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - ranitidine hydrochloride - oral tablet - 150mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - ranitidine hydrochloride - oral tablet - 150mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharma uk ltd - ranitidine hydrochloride - oral tablet - 150mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

sterwin medicines - ranitidine hydrochloride - oral tablet - 150mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - ranitidine hydrochloride - oral tablet - 150mg

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

physician therapeutics llc - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine hydrochloride 150 mg - indications and usage ranitidine tablets, usp is indicated in: 1. short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). 4. short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulce